Odonate Therapeutics

General Information


We are a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Our initial focus is on the development of tesetaxel, a novel chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer. Tesetaxel has several potential therapeutic advantages over currently available taxanes, including: oral administration with a low pill burden and a patient-friendly dosing regimen; a formulation that does not contain solubilizing agents that are known to cause hypersensitivity (allergic) reactions; and improved activity against chemotherapy-resistant tumors.


Employees: 50
Founded: 2013
Contact Information
Address 4747 Executive Drive, Suite 510, San Diego, CA 92121, US
Phone Number (858) 731-8180
Web Address http://www.odonate.com
View Prospectus: Odonate Therapeutics
Financial Information
Market Cap $645.4mil
Revenues $0 mil (last 12 months)
Net Income $-18.9 mil (last 12 months)
IPO Profile
Symbol ODT
Exchange NASDAQ
Shares (millions): 6.3
Price range $24.00 - $24.00
Est. $ Volume $150.0 mil
Manager / Joint Managers Goldman Sachs/ Jefferies
CO-Managers Cowen
Expected To Trade: 12/7/2017
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change